Status:
COMPLETED
Symbicort Single Inhaler Therapy for Asthma in a General Practice Setting
Lead Sponsor:
AstraZeneca
Conditions:
Asthma
Eligibility:
All Genders
18+ years
Phase:
PHASE3
Brief Summary
The primary objective is to compare the effects of Symbicort SiT and treatment according to NHG-guidelines on bronchial hyperresponsiveness in asthmatic patients, as measured by PD20 histamine, and to...
Eligibility Criteria
Inclusion
- diagnosis of mild to moderate asthma, FEV1 ³ 60% of predicted normal values pre-bronchodilator, daily use of inhaled GCS during the last 3 months
Exclusion
- Regular need of \>4 inhalations of a short-acting b2-agonist/day, known or suspected hypersensitivity to any of the investigational drugs or inhaled lactose, use of any b-blocking agent, having smoked ³10 pack-years
Key Trial Info
Start Date :
September 1 2003
Trial Type :
INTERVENTIONAL
End Date :
December 1 2006
Estimated Enrollment :
100 Patients enrolled
Trial Details
Trial ID
NCT00235911
Start Date
September 1 2003
End Date
December 1 2006
Last Update
January 24 2011
Active Locations (2)
Enter a location and click search to find clinical trials sorted by distance.
1
Research Site
Appingedam, Netherlands
2
Research Site
Groningen, Netherlands